title: Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke.
abstract: BACKGROUND
  This study estimates the risk of stroke within 5 years of newly diagnosed dementia among elderly persons aged 65 and above. We examined the relationship between antipsychotic usage and development of stroke in patients with dementia.
  
  
  METHODS
  We conducted a nationwide 5-year population-based study using data retrieved from the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan. The study cohort comprised 2243 patients with dementia aged ≥65 years who had at least one inpatient service claim or at least 2 ambulatory care claims, whereas the comparison cohort consisted of 6714 randomly selected subjects (3 for every dementia patient) and were matched with the study group according to sex, age, and index year. We further classified dementia patients into 2 groups based on their history of antipsychotic usage. A total of 1450 patients were classified into the antipsychotic usage group and the remaining 793 patients were classified into the non-antipsychotic usage group. Cox proportional-hazards regressions were performed to compute the 5-year stroke-free survival rates after adjusting for potentially confounding factors.
  
  
  RESULTS
  The dementia patients have a 2-fold greater risk of developing stroke within 5 years of diagnosis compared to non-dementia age- and sex-matched subjects, after adjusting for other risk factors (95% confidence interval (CI) = 2.58-3.08; P<.001). Antipsychotic usage among patients with dementia increases risk of stroke 1.17-fold compared to patients without antipsychotic treatment (95% CI = 1.01-1.40; P<.05).
  
  
  CONCLUSIONS
  Dementia may be an independent risk factor for stroke, and the use of antipsychotics may further increase the risk of stroke in dementia patients.
authors.affiliation: Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
authors.forename: Mu-En
authors.initials: ME
authors.lastname: Liu
authors.forename: Shih-Jen
authors.initials: SJ
authors.lastname: Tsai
authors.forename: Wei-Chiao
authors.initials: WC
authors.lastname: Chang
authors.forename: Chun-Hung
authors.initials: CH
authors.lastname: Hsu
authors.forename: Ti
authors.initials: T
authors.lastname: Lu
authors.forename: Kuo-Sheng
authors.initials: KS
authors.lastname: Hung
authors.forename: Wen-Ta
authors.initials: WT
authors.lastname: Chiu
authors.forename: Wei-Pin
authors.initials: WP
authors.lastname: Chang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D016208:Databases, Factual; D003704:Dementia / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007344:Insurance Claim Reporting / Q000706:statistics & numerical data; D008297:Male; D016016:Proportional Hazards Models; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D016019:Survival Analysis; D013624:Taiwan / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents